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Purpose: Myocardial T1 relaxation time (T1 time) and extracellular volume fraction (ECV) are altered in patients with
diffuse myocardial fibrosis. The purpose of this study was to perform an intra-individual assessment of normal T1
time and ECV for two different contrast agents.
Methods: A modified Look-Locker Inversion Recovery (MOLLI) sequence was acquired at 3 T in 24 healthy subjects
(8 men; 28 ± 6 years) at mid-ventricular short axis pre-contrast and every 5 min between 5-45 min after injection of
a bolus of 0.15 mmol/kg gadopentetate dimeglumine (Gd-DTPA; Magnevist®) (exam 1) and 0.1 mmol/kg
gadobenate dimeglumine (Gd-BOPTA; Multihance®) (exam 2) during two separate scanning sessions. T1 times were
measured in myocardium and blood on generated T1 maps. ECVs were calculated as ΔR1myocardium=ΔR1blood
  
1−hematocritð Þ.
Results: Mean pre-contrast T1 relaxation times for myocardium and blood were similar for both the first and second
CMR exam (p> 0.5). Overall mean post-contrast myocardial T1 time was 15 ± 2 ms (2.5 ± 0.7%) shorter for Gd-DTPA
at 0.15 mmol/kg compared to Gd-BOPTA at 0.1 mmol/kg (p< 0.01) while there was no significant difference for T1
time of blood pool (p> 0.05). Between 5 and 45 minutes after contrast injection, mean ECV values increased linearly
with time for both contrast agents from 0.27 ± 0.03 to 0.30 ± 0.03 (p< 0.0001). Mean ECV values were slightly higher
(by 0.01, p< 0.05) for Gd-DTPA compared to Gd-BOPTA. Inter-individual variation of ECV was higher (CV 8.7% [exam
1, Gd-DTPA] and 9.4% [exam 2, Gd-BOPTA], respectively) compared to variation of pre-contrast myocardial T1
relaxation time (CV 4.5% [exam 1] and 3.0% [exam 2], respectively). ECV with Gd-DTPA was highly correlated to ECV
by Gd-BOPTA (r = 0.803; p< 0.0001).
Conclusion: In comparison to pre-contrast myocardial T1 relaxation time, variation in ECV values of normal subjects
is larger. However, absolute differences in ECV between Gd-DTPA and Gd-BOPTA were small and rank correlation
was high. There is a small and linear increase in ECV over time, therefore ideally images should be acquired at the
same delay after contrast injection.
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Table 1 Volunteer (n = 24) characteristics for both exams
Characteristics Gd-DTPA Gd-BOPTA
(exam 1) (exam 2)
Age in years, mean ± SD 28± 6
Male, n (%) 8 (33)
Weight in kg, mean ± SD 69.0 ± 12.7 69.0 ± 13.1
Hematocrit in %, mean ± SD 39.8 ± 3.9 39.5 ± 3.9
Heart rate in bpm*, mean ± SD 62 ± 8 61 ± 12
Creatinine in mg/dl, mean ± SD 0.8 ± 0.2 0.8 ± 0.2
Gadolinium dose in ml, mean ± SD 20.4 ± 4.1 13.9 ± 2.6
*during the MOLLI sequence prior to contrast injection.
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Delayed gadolinium enhancement is an established tech-
nique in cardiovascular magnetic resonance (CMR) to
demonstrate focal myocardial scar/ fibrosis [1]. Since a
correlation between post-contrast myocardial T1 relaxation
time (T1 time) and histologically proven fibrosis has been
demonstrated [2], the potential of quantitative analysis of
diffuse myocardial fibrosis by means of CMR has been pos-
tulated [3]. Alteration of myocardial T1 times compared
with values of normal subjects has been reported in associ-
ation with adult congenital heart disease [4], cardiac amyl-
oidosis [5], myocardial involvement in systemic lupus
erythematosus [6], and chronic aortic regurgitation [7].
After gadolinium injection, contrast dose and type in-
fluence T1 times [8]. So far there is also no standardized
method of reporting T1 times. While some authors use
absolute values [3,5] others prefer the partition coefficient
[9], extracellular volume fraction (ECV) [10] or fibrosis
index [4]. As opposed to absolute T1 times, the ECV of
myocardium is postulated to be constant over time under
equilibrium conditions [11]. ECV values are calculated
from the change in relaxation rate (R1=1/T1) of blood
and myocardium corrected for the hematocrit. ECV is
reported as a fraction and ranges from 0 (all fluid) to 1
(solid with no extracellular component) [11,12].
Gadopentetate dimeglumine (Gd-DTPA) is a gadolin-
ium based contrast agent commonly used at a dose of
0.15 – 0.2 mmol/kg in CMR. [3,7] Due to a higher relax-
ivity [13] related to protein binding, some publications
report gadobenate dimeglumine (Gd-BOPTA) at a lower
dose of 0.1 mmol/kg for CMR [14,15].
The purpose of this study was to determine normal ECV
and T1 values for healthy volunteers, to assess stability of
ECV over time and to evaluate the influence of two con-
trast agents with different relaxivity on calculated ECV.
Methods
Study population and image acquisition
24 healthy subjects (8 men; mean age ± SD, 28±6; age
range 19–40) were imaged in two separate sessions using a
3T scanner (Verio, Siemens Medical Solutions, Erlangen,
Germany) and a 32-channel cardiac coil. Volunteers were
recruited via the Volunteer Recruitment Office of the
National Institutes of Health. All study participants
signed informed consent as part of an ongoing institu-
tional review board approved study. All participants
underwent two different scanning sessions for Gd-DTPA
and Gd-BOPTA evaluation. Images were acquired pre-
contrast and every 5 minutes between 5 and 45 minutes
after injection of a bolus of 0.15 mmol/kg Gd-DTPA
(Magnevist, Bayer Healthcare; concentration 0.5 mol/l)
(exam 1) and 0.1 mmol/kg Gd-BOPTA (Multihance,
Bracco Diagnostics; concentration 0.5 mol/l) (exam 2),
respectively. The MOLLI sequence was acquiredrepetitively as a single mid-ventricular short axis image
at the same slice position in mid- to end-diastole. Delay
time varied depending on heart rate.
The aromatic ring of Gd-BOPTA enables weak plasma
protein binding resulting in a higher relaxivity in
plasma/blood compared to Gd-DTPA [16-18]. Several
studies have demonstrated that a lower dose of Gd-
BOPTA has similar diagnostic efficacy compared to Gd-
DTPA at a higher dose [15,19,20]. In order to achieve
somewhat similar post-contrast T1 times and to be con-
sistent with the institutions’ practice, we used a lower
dose of Gd-BOPTA (0.1 mmol/kg) compared to Gd-
DTPA (0.15 mmol/kg). These dose values have also pre-
viously been used in the literature [3,11,14,15]. Both con-
trast agents were injected intravenously at 2 ml/s using a
power injector and followed by a 30 ml saline bolus
administered at the same flow rate. The short MOLLI se-
quence used in the current study was adapted from that
introduced by Messroghli et al. and has been described
previously [21,22]. Short MOLLI acquired 8 images at
different inversion times using the following scan para-
meters: TE/TR 1.03/2.4 ms; flip angle 35°; bandwidth
1002 Hz/Px; minimum TI 125 ms; TI increment 80 ms;
image acquisition time 217 ms; FOV 360 × 288 mm2;
pixel size 2.3 × 1.9 mm2 (interpolated to 1.2 × 1.0 mm2);
slice thickness 8 mm; iPAT factor (GRAPPA) 2.
All study participants underwent 12 lead ECG as well
as a history and physical examination prior to each CMR
study. All study participants were determined to be free
of clinical cardiovascular or systemic disease and had a
normal electrocardiogram. A CMR examination per-
formed prior to the current study showed normal global
and regional function. Myocardial late gadolinium en-
hancement imaging did not show a myocardial scar in
any of the subjects. Table 1 shows further characteristics
of the study subjects.Image analysis
T1 maps were generated using MRmap [23]. Manual mo-
tion correction was performed when necessary. Pre-
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might not fully recover when the same sampling schemes
are used compared to 1.5T. In a phantom study recently
published it has been demonstrated that for a heart rate of
60 bpm, the difference between MOLLI- and inversion-
recovery spin-echo (IR-SE) -derived T1 times were smaller
than 5% for a T1 time less than 500 ms. The difference
increased to 5-10% for T1 times between 500-1500 ms,
and the difference continued to increase for T1 times of
more than 1500 ms [22]. Further, underestimation of T1
time increases with increasing heart rate. Therefore in the
current study heart rate correction was performed for pre-
contrast T1 times of myocardium and blood. The heart
rate correction algorithm was based on the phantom data
published previously by Lee et al. [22]. MOLLI-derived T1
relaxation times of different heart rates were fitted to IR-
SE-derived T1 relaxation times using 2nd order polyno-
mial fitting. An Additional file 1 shows in detail how heart
rate correction was performed [see Additional file 1]. Pre-
contrast in vivo MOLLI –derived T1 relaxation times were
corrected using this function. T1 maps were transferred to
QMass V.7.2 (Medis Medical Imaging Systems, Nether-
lands). Left ventricular endocardial and epicardial contours
were drawn manually while segments were defined auto-
matically by the software after marking the border between
segment 7 and 8 (Figure 1). T1 times at the mid short axis
slice of the left ventricle were determined for each segment
(American heart association [AHA] segments 7–12) [24].
Segments with severely impaired image quality related to
primarily motion artifacts involving the whole segment
were identified. An overall myocardial T1 time for each
slice was calculated, excluding segments with severely
impaired image quality. T1 time of the blood pool was
measured by manually drawing a region of interest in the
blood pool of the left ventricular cavity excluding papillary
muscles. For 10 randomly chosen subjects, measurements
were performed by a second independent reader to assess
inter-observer variability. The ECV was calculatedFigure 1 T1 maps with measurements. T1 map pre- (A) and post-contraasΔ R1 myocardium =Δ R1 blood  1 − hematocritð Þ, where ΔR1
myocardium=1/T1myocardium pre contrast - 1/T1myocardium post
contrast and ΔR1blood = 1/T1blood pre contrast - 1/T1blood post
contrast [12].Statistical analysis
Statistical analysis was performed using SPSS (IBM stat-
istical software; version 19). Continuous variables are
expressed as mean ± SD. Pre-contrast myocardial T1
times for Gd-DTPA and Gd-BOPTA were compared
using a paired t-test. Post-contrast T1 times were ana-
lyzed using linear mixed-model analyses with separate
models incorporating the log transformed T1 times
for blood and myocardium as the dependent variable,
including the contrast agent and time as the predic-
tors. Linear mixed-model analysis of the ECV values
as the outcome with contrast type and time as inde-
pendent variables was also performed in order to
identify group related differences. After adjustment of
ECV values for time, nonparametric analysis was used to
assess the correlation/ rank of ECV for Gd-DTPA versus
Gd-BOPTA using Spearman’s correlation coefficient.
Bland-Altman plots were generated for each time point
after contrast injection to compare ECV of exam 1 and
exam 2. A p-value of <0.05 was considered to be statisti-
cally significant. To assess inter-individual variation the
coefficient of variation (CV) was calculated for T1 relax-
ation time of myocardium and blood before and after con-
trast injection and for ECV values.
To compare inter-observer agreement, the intraclass
correlation coefficient (ICC) using a two-way random
model (ICC< 0.40 = poor; ICC≥ 0.40 to 0.75 = fair to
good; ICC> 0.75 = excellent agreement) was calculated.Results
672T1 maps at the pre-specified time points were avail-
able for evaluation; 4 T1 maps were not available due tost (B) with left ventricular endocardial and epicardial contours.
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quality 52/4032 (1.3%) segments were excluded from fur-
ther analysis. The mean time between intra-individual
repeat scans was 51 ± 34 days.
Normal T1 relaxation time of myocardium and blood:
Gd-DTPA and Gd-BOPTA
As expected, prior to contrast injection, mean T1 relaxation
times for myocardium were similar for both the first and
second CMR exam (1286±59 and 1273±39, respectively,
p =0.2). Also, blood T1 times were similar at exams 1 and
2 (2074±139 and 2097±112, respectively, p =0.4).
Figure 2A shows the mean ± SD of T1 relaxation times
for myocardium and blood pre-contrast and over time
between 5 and 45 minutes after contrast injection for
exams acquired with Gd-DTPA (exam 1) and Gd-
BOPTA (exam 2). The mean myocardial T1 relaxation
time was 15 ± 2 ms (2.5 ± 0.7%) lower for Gd-DTPA com-
pared to Gd-BOPTA (p< 0.01) averaged over all time
points after contrast injection (5 min to 45 min). For
blood pool, T1 relaxation time was not significantly dif-
ferent between Gd-DTPA and Gd-BOPTA (p> 0.05).
Coefficient of variation (CV) of pre-contrast T1 relax-
ation time of myocardium for exam 1 was 4.5% and for
exam 2 3.0%. Overall CV of post-contrast myocardial T1
relaxation times averaged over all time points was 7.0%Figure 2 Change in mean T1 time ± SD over time. Change in T1 time o
myocardium Gd-DTPA; black circle (A) = blood Gd-DTPA; grey diamond (A)
diamond (B) = ECV Gd-DTPA; grey square (B) = ECV Gd-BOPTA.(exam 1, Gd-DTPA) and 5.9% (exam 2, Gd-BOPTA). CV
of T1 relaxation times measured in blood pre-contrast
was 6.5% (exam 1) and 5.5% (exam 2), respectively. CV
of post-contrast T1 relaxation time of blood averaged
over all time points was 12.2% (exam 1, Gd-DTPA) and
9.5% (exam 2, Gd-BOPTA), respectively.
Normal ECV values: Gd-DTPA and Gd-BOPTA
On average, ECV of Gd-DTPA was slightly greater (by
0.01) than that of Gd-BOPTA between 5 and 45 min (p
< 0.05). The observed range of the normal ECV values
averaged over all time points was about 30% of the mean
value. However, subjects with higher ECV values for Gd-
DTPA were also the subjects who tended to show higher
ECV values for Gd-BOPTA (Spearman’s correlation coeffi-
cient = 0.803, p< 0.0001). Bland-Altman plots demon-
strated a good agreement of ECV values obtained in exam
1 and exam 2 for all time points (Figure 3). CV of ECV was
8.7% (exam 1, Gd-DTPA) and 9.4% (exam 2, Gd-BOPTA),
respectively.
Mean ECV of both gadolinium agents (Gd-DTPA and
Gd-BOPTA) increased linearly over time (p< 0.0001) (Fig-
ure 2B). Between the 5 to the 45 minute acquisition, mean
values for both contrast agents increased from 0.27± 0.03
to 0.30± 0.03. In practice, ECV values will likely be
obtained at only 1 time point after gadolinium injection.f myocardium and blood (A) and ECV (B) over time. Black square (A) =
= myocardium Gd-BOPTA; grey circle (A) = blood Gd-BOPTA; black
Figure 3 Bland-Altman plots comparing ECV values of exam 1 (Gd-DTPA) and exam 2 (Gd-BOPTA). Bland-Altman plots of the acquisitions
at 5 min (A), 15 min (B), and 45 min (C) are shown exemplarily.
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values yielded the following time correction factors:
ECVcalc¼ ECVacq  0:0007 tacqtcalc
 
for GdDTPA at a dose of 0:15mmol=kgð Þ
ECVcalc¼ ECVacq  0:0008 tacqtcalc
 
for Gd BOPTA at a dose of 0:1mmol=kgð Þwhere tacq=time (in minutes) after contrast injection when
MOLLI was acquired, tcalc=time (in minutes) after contrast
injection of interest, ECVacq=ECV at the time point tacq
and ECVcalc=ECV at the time point tcalc.
Inter-observer agreement
Inter-observer agreement was excellent for measure-
ments of T1 relaxation time for myocardium and blood.
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0.997 (exam 2, Gd-BOPTA), respectively. ICC for blood
was 0.999 (exam 1, Gd-DTPA) and 0.998 (exam 2, Gd-
BOPTA).
Discussion
The current study evaluates the range of normal
values for T1 time and ECV at 3 Tesla for two in
CMR commonly used gadolinium containing contrast
agents, namely Gd-DTPA at a dose of 0.15 mmol/kg
and Gd-BOPTA at 0.1 mmol/kg for an ethnically di-
verse group of young adults (≤ 40 years). Differences
in ECV between the two contrast agents were small
but significant (mean difference, 0.01). However, the
range of normal ECV’s varied by approximately one
third of the mean value. In addition, healthy subjects
who had higher ECV values for Gd-DTPA also ranked
higher in their ECV values for the Gd-BOPTA exam-
ination, performed on average 51 ± 34 days later. ECV
showed a small but nearly linear increase over time
between 5 and 45 minutes after both Gd-DTPA and
Gd-BOPTA.
T1 times and ECV of Gd-DTPA versus Gd-BOPTA
It is known that T1 relaxation time of a given tissue is
longer at 3T compared to 1.5T [25]. This explains why
myocardial pre-contrast T1 times acquired in the current
study are longer compared to previous publications at
1.5T [3]. It has been demonstrated that particularly at
high heart rates and long T1 relaxation times MOLLI
underestimates true T1 time [22]. Therefore in the
current study pre-contrast T1 times were corrected for
heart rate. This explains why average myocardial pre-
contrast T1 relaxation time is about 10% longer com-
pared to values reported by Piechnik et al.[26]. Com-
pared to Lee et al. values are 2% shorter, which might be
explained by the higher mean age of 36 ± 13 years in the
afore mentioned study compared to 28 ± 6 years in the
current study [22]. Diffuse fibrosis is known to occur
with “normal aging” of the heart and a correlation be-
tween age and the extracellular volume fraction has
already been demonstrated [27].
Myocardial T1 relaxation times have been demon-
strated to correlate with histologically proven fibrosis
[2] and correlation between ECV and histological fi-
brosis was shown [10]. Although T1 relaxation times of
equimolar doses of Gd-BOPTA are significantly lower
compared to Gd-DTPA, differences in ECV have not pre-
viously been determined. After dose adjustment, in the
current study we observed small but slightly higher ECV
values for Gd-BOPTA compared to Gd-DTPA by .01
(mean difference, or approximately 4% of the mean values)
(Figure 2B). The binding of Gd-BOPTA to human serum
albumin results in a lower molecular tumbling rate of themolecule and a longer rotational MR correlation time lead-
ing to an increased relaxivity [28]. Since albumin is mainly
present in blood, the distribution between blood and myo-
cardium is expected to be different between Gd-BOPTA
and Gd-DTPA whereas pre-contrast values are equal. This
should affect the ratio of the change in relaxation rate of
myocardium and blood and might explain the difference in
ECV values.
Variation in ECV over time
Calculation of ECV values is based on the assumption of
a two-compartment model. Due to a rapid exchange, a
steady state with equal contrast concentration in the
intravascular compartment and the interstitial compart-
ment is supposed to be established [11,16,29]. There is
ongoing debate whether equilibrium can only be
achieved by a continuous contrast infusion technique or
if a single bolus is sufficient to establish equilibrium
within a certain time after contrast injection [27,30,31].
Our results show the two compartment model may be
limited in that there was a continuous increase of ECV
values over time for both Gd-DTPA and Gd-BOPTA
after bolus injection of contrast (Figure 2B). Schelbert
et al. also reported a small but statistically significant
change of Ve (extravascular extracellular volume frac-
tion) after bolus infusion of gadolinium. In their study,
the increase over 30 minutes was 0.6%; in the current
study, the increase over 45 minutes was about 0.03 (11%)
for both agents. There are several possible explanations
for the variation in magnitude of ECV increase over time
between the two studies: First, the group of volunteers in
the current study consisted only of healthy young adults.
Schelbert et al. included a heterogeneous group of 10
study subjects only, including four older volunteers (66–
81 years) with “significant comorbidity” and potentially
reduced renal function (lower limits of normal) and sub-
sequently slower contrast excretion in comparison to
young healthy subjects. Second, Schelbert et al realized a
significant increase in Ve over 30 minutes whereas in the
current study the increase of 11% was realized between
minute 5 and 45 after contrast injection. Since ECV
increases linearly over time, the increase is larger with
increasing duration of the observation period. And fi-
nally in the afore mentioned study it is not reported
whether the increase of 0.6% was absolute or relative.
Since Ve and ECV, respectively is a ratio/percentage
results can be reported in different ways, what might
lead to confusion. In the current study the absolute in-
crease in ECV till minute 45 was 0.03 or 3%, relative in-
crease was 11%.Ugander et al describe that in their study
ECV remained stable over time after contrast injection.
Apparently comparison was performed only between
values of one time point and the following but not over
the entire observation period of 25 min only [32]. In the
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of the y-axis is large (0-100%) and a smaller increase in
ECV over time such as in the current study might not
become obvious. Further, Ugander et al included only 11
volunteers in this part of their analysis whose age range
is not mentioned.
A possible reason for the lack of equilibrium is that
renal clearance might be faster than exchange rate be-
tween intravascular and interstitial compartment. Further,
gadolinium based contrast agents also penetrate into
other spaces such as synovial fluid and bone hampering
maintenance of equilibrium [33-35]. Clinically, an increase
in ECV over 45 minutes may be relevant if the MOLLI se-
quence is not acquired at identical post-contrast delay
times. Broberg et al. measured a “fibrosis index” of
0.32 ± 0.05 in patients with different types of congenital
heart disease and an index of 0.25 ± 0.02 in normal con-
trols [4]. Messroghli et al. examined myocardial T1 times
in rats before and after angiotensin II infusion and mea-
sured mean ECV values of 0.17 and 0.23, respectively [10].
In both studies mean differences were in the order be-
tween 0.06 and 0.07. Since inter-individual variation was
rather high it seems important to measure ECV values at
consistent times after bolus injection.Inter-individual variation
We demonstrated that concordance (or rank order) of ECV
values between exam 1 (Gd-DTPA) and exam 2 (Gd-
BOPTA) was high. For example, those subjects with a rela-
tively higher ECV value for Gd-DTPA also had a relatively
higher ECV value for Gd-BOPTA. This concordance be-
tween ECV values over the two exams was reflected by a
high Spearman’s correlation coefficient of 0.803 (p< 0.0001,
assessed over all time points). Blant-Altman plots (Figure 3)
further demonstrate a good agreement between exams but
a large inter-individual variation of ECV.
Inter-individual variation of ECV was higher (CV 8.7%
[exam 1, Gd-DTPA] and 9.4% [exam 2, Gd-BOPTA], re-
spectively) compared to variation of pre-contrast myocar-
dial T1 relaxation time (CV 4.5% [exam 1, Gd-DTPA]
and 3.0% [exam 2, Gd-BOPTA], respectively). According
to previous publications the mean difference between
maximum and minimum ECV values averaged over all
time points in healthy subjects was approximately 0.09
for Gd-DTPA and 0.11 for Gd-BOPTA [27]. The some-
what broad range of ECV must be considered when
identifying a cut-off or threshold value for abnormally
increased or decreased ECV.
Since there was a high correlation and good agreement
of ECV values between exam 1 and 2 we conclude that
the large inter-individual variation in ECV values is a real
finding and not related to noise. Further, Schelbert et al.
also reported a large inter-individual variation of theextravascular extracellular volume fraction (Ve) [27]. The
large inter-individual variation of ECV is most probably a
consequence of the large inter-individual variation of the
post-contrast T1 relaxation time of blood. Variation in
post-contrast T1 time of blood is most likely related to
inter-individual differences in hydration, renal excretion
and distribution of contrast into other spaces such as syn-
ovial fluid and bone.
There are several limitations of this study. Our T1
times and ECV values are for younger individuals
scanned at 3T. The pharmacokinetics of these gadolin-
ium contrast agents may vary for older subjects or indi-
viduals with renal dysfunction. Given the somewhat large
range of ECV values relative to the mean values in this
normal population, the study size (n = 24) yields only an
approximation to the 95% confidence intervals of the
population. The normal values given are valid only for
the doses of gadolinium that were studied (0.10 mmol/kg
for Gd-BOPTA and 0.15 mmol/kg for Gd-DTPA). Ideally
order of exams should be random. Given our results,
intra-individual reproducibility seems to be an important
parameter that should be established for planning of lon-
gitudinal studies. To test intra-individual reproducibility
ideally volunteers should be scanned twice with the same
protocol, contrast dose and type.Conclusions
Normal ECV values are affected by several factors:
First, there is a large inter-individual variation of about
30% of the mean. The smaller inter-individual variation
in pre-contrast T1 times and the ability to discriminate
between normal individuals and a disease population
with diffuse myocardial fibrosis requires further ana-
lysis. Second, there is a small but significant linear in-
crease in ECV with time in the first 45 minutes after a
bolus of gadolinium of 11% necessitating of either
careful attention to imaging delay time or post-hoc
correction for this variability to permit serial compari-
son. And third, there is a minor but significant differ-
ence with contrast agent of 2% between Gd-DTPA at
0.15 mmol/kg and Gd-BOPTA at 0.1 mmol/kg. How-
ever, the ECV values of Gd-BOPTA and Gd-DTPA were
quite similar, and subjects with high (or low) ECV values
had similar values with both contrast agents over a
mean follow-up period of almost 2 months. Subsequent
comparisons to patients with cardiomyopathies will be
necessary to determine the clinical utility of these surro-
gate markers of myocardial fibrosis.Additional file
Additional file 1: Heart rate correction. Detailed description of heart
rate correction of pre-contrast T1 times.
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